卡培他滨联合顺铂治疗胃癌28例临床观察

Clinical Observation of Chemotherapy Combined with Capecitabine plus Cisplatin in the Treatment of Advanced Gastric Carcinoma

目的 观察卡培他滨联合顺铂治疗晚期胃癌的近期疗效和毒副反应。方法 初治和复治的晚期胃癌28例,卡培他滨2 000 mg/m^2口服d1-14;顺铂75 mg/m^2静脉滴注d1,21 d为1个周期,连用2周后评价疗效。结果 总有效率53.6%（15/28）。主要毒副反应为胃肠道反应、手足综合征、Ⅲ-Ⅳ度的白细胞减少各占7.2%（2/28）。结论 治疗晚期胃癌,卡培他滨联合顺铂21 d方案是有效、经济和安全的。

Objective The purposes of this study were to evaluate the efficacy and toxicity of the combination of capecitabine and cisplation in the treatment of patients with advanced gastric carcinoma. Methods 28 previous patients with advanced gastric carcinoma were treated with eapeeitabine plus eisplatin. Chemotherapy consisted of eapeeitabine 2 000 mg/（m2 · d） given orally twice a day on days 1 to 14 of a 21-day cycle, concurrently with eisplatin 75 mg/m^2 intravenously on day 1, the evaluation of efficacy and toxicity were performed on all patients after 2 cycles. Results The tumor response rate observed in this study was 53, 6% （15/28）. Commonly occurring adverse events included nausea and vomiting, hand-foot syndrome and grade Ⅲ-Ⅳ neutropenia（2/28）. Conclusions The regimen eapeeitabine and eisplatin had shown activity in patients with advanced gastric carcinoma. The toxicity was mild and tolerable.